Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Average Recommendation of “Hold” by Analysts

Shares of Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) have been assigned a consensus recommendation of “Hold” from the eleven analysts that are currently covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $4.79.

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 price objective on shares of Marinus Pharmaceuticals in a report on Thursday, November 14th. StockNews.com assumed coverage on Marinus Pharmaceuticals in a research note on Saturday, February 22nd. They issued a “sell” rating for the company. Finally, HC Wainwright reissued a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th.

Marinus Pharmaceuticals Stock Performance

Shares of NASDAQ:MRNS opened at $0.55 on Thursday. The firm has a market capitalization of $30.32 million, a PE ratio of -0.22 and a beta of 1.03. Marinus Pharmaceuticals has a 52-week low of $0.22 and a 52-week high of $10.50. The firm has a fifty day moving average of $0.51 and a 200 day moving average of $0.84.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the company. World Investment Advisors LLC purchased a new position in shares of Marinus Pharmaceuticals in the third quarter valued at about $104,000. Virtu Financial LLC bought a new stake in shares of Marinus Pharmaceuticals in the fourth quarter worth about $36,000. GABELLI & Co INVESTMENT ADVISERS INC. purchased a new position in Marinus Pharmaceuticals during the 4th quarter valued at about $54,000. JPMorgan Chase & Co. raised its position in Marinus Pharmaceuticals by 1,968.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 133,191 shares of the biopharmaceutical company’s stock valued at $234,000 after purchasing an additional 126,752 shares during the last quarter. Finally, Deltec Asset Management LLC purchased a new stake in Marinus Pharmaceuticals in the 4th quarter worth approximately $107,000. Hedge funds and other institutional investors own 98.80% of the company’s stock.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.